Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

• Status: Recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imago BioSciences,Inc.

Criteria

Inclusion Criteria:

1. Completed at least one Treatment Period (TP) in a prior bomedemstat MPN protocol (such as, but not limited to, IMG-7289-CTP-102 or IMG-7289-CTP-201).

2. In the estimation of the Investigator, the risk-benefit favors continued dosing with bomedemstat.

Exclusion Criteria:

1. Ongoing participation in another investigational study (except observational studies).

2. A history of non-compliance in a prior bomedemstat study (excluding dose suspensions that were medically warranted).

3. Current use of a prohibited medication (e.g., romiplostim).

4. Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's safety, ability to give informed consent, or comply with the trial protocol.

5. Females who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.

6. Women of childbearing potential (WOCBP) and fertile men unwilling to agree to use an approved method of contraception from time of enrollment until 14 days after last bomedemstat dose.